COR Cencora Inc

Cencora (formerly AmerisourceBergen) is one of the world's largest pharmaceutical distribution companies, serving health systems, retail pharmacies, and specialty medical practices. Sector: Healthcare.

Cencora Inc (COR) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 22.13%, WACC is 8.02%, and the economic spread is 14.11%. On balance, the spread between ROIC and WACC is solidly positive — reinvestment is adding value rather than diluting it. Supporting metrics show ROE at 127.97% and ROA at 2.77%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

Valuation currently screens at trailing P/E of 39.01, forward P/E of 18.32, PEG of 1.75. The gap between trailing and forward multiples is wide, suggesting the market is pricing meaningful earnings expansion over the coming year. Growth-adjusted valuation is in a reasonable range, with the multiple broadly in line with expected earnings expansion. The aggregate current ratio of 0.92 reflects tighter near-term liquidity — a factor worth monitoring if macro conditions tighten. The valuation profile here is neither obviously cheap nor dramatically expensive — a setup where the return case is built more on earnings delivery than on re-rating potential.

From gross to free cash flow, gross margin sits at 3.65%, operating margin at 1.24%, and free cash flow margin at 1.11%. At this level, gross margins signal that pricing power is constrained and direct cost management is a key performance driver. At this level, operating margins signal that earnings quality is limited — a feature of growth-stage or restructuring businesses. The company's FCF margin signals that most revenue is being consumed before reaching the free cash flow line — a feature of early-stage or heavily invested businesses. The margin profile is mixed, with some layers more resilient than others and less room for execution slippage.

Combining revenue momentum with analyst targets, the estimated 12-month price change of 21.88%, where consensus expectations favor gradual appreciation over the next year, while TTM revenue growth of 5.45% reflecting moderate but reliable revenue progress across the company. Separating operating reality from market-implied expectations is useful here — they can diverge meaningfully when sentiment shifts. The forward return case hinges on whether the operating reality stays close enough to analyst assumptions for those targets to remain credible. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The fundamental case holds up across most key dimensions — the combination of positive economic spread, reasonable valuation, and analyst support is constructive.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.